1. A Revolution in Mind
June 2015
CSNX: HSM
OTCQB: HSDT

2. Disclaimer
This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Helius Medical Technologies expectations and projections. The Ontario Securities Commission has neither approved nor disapproved the information contained in this presentation. Except for statements of historical fact relating to the Company, certain information contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of medical devices and FDA or other international regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with medical device product approvals in multiple jurisdictions. The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to place undue reliance on forward-looking statements.

3. Overview Helius Medical Technologies
Medical device company focused on neurological wellness and the development of unique, non-invasive, technologies to enable the brain to heal itself
Portable Neuromodulation Stimulator or PoNS™ Device
Electrode-covered oral device delivering specially-patterned nerve impulses to a patient's brain through appliance placed on the tongue
PoNS treats neurological symptoms caused by disease or trauma
Clinical experience with over 200 patients
U.S. Armed Forces Collaboration
Collaborative Research and Development Agreement (CRADA)
Army our development partner and first customer
Development and Clinical Trials
Testing and studies, to date, provide encouraging indications
Clearance by FDA expected Q3/Q4 2016

4. Management Team Philippe Deschamps
President, CEO
28 years in the Health Sciences industry
MediMedia Health Marketing Services
President and CEO - GSW Worldwide operations
Director of Neuroscience Marketing at Bristol-Myers Squibb
Jonathan Sackier Chief Medical Officer
30 years in the Health Sciences industry
An innovator and pioneer of new technologies
Has helped build several companies including medical technology, research and product-design and medical contract sales organizations
Experienced management team with expertise in healthcare and business development

5. Scientific Team: Inventors of PoNS TM Technology
TACTILE COMMUNICATION AND NEUROREHABILITATION LABORATORY
UNIVERSITY OF WISCONSIN–MADISON
Department of Biomedical Engineering
Founded in 1992 by a pioneer of Neuroplasticity, Dr. Paul Bach-Y-Rita
Research center using various areas of science to study the theory and application of applied neuro­plasticity, the brain’s ability to reorganize in response to new information, needs, and pathways
Research objective to develop solutions for sensory and motor disorders
TCNL Project Directors:
Mitchell E. Tyler, Kurt Kaczmarek, Yuri P. Danilov
>20 years of individual experience in their respective fields of neuroscience, biomedical science, and engineering.
Co-discoverers of the retention effect and neurorehabilitation potential of tongue electrotactile stimulation
Recognized experts in electrotactile stimulation
Invented core tongue display technology
Over 65 years combined experience in neuroscience, biomedical science, and engineering

6. Important Core Concept - Neuroplasticity
The ability of the brain to remain “plastic”, enabling new learning and the capacity to compensate for damage
The PoNS Device provides stimulation to the brain-stem and other brain structures via the cranial nerves
We believe this stimulation, when combined with a “task” (physical, cognitive or mental exercises)
enhances the brain’s self recovery mechanism
“re-engage” existing neural networks
reinforces new learning
PPAE guidance:
This is a stacked Column chart showing Army, DHP & Other funding in $M
Other: is funds POM’d by others
RAD2 Chart version from “RAD2 Program Plan Supporting Spreadsheet_bjw_rwp 25June12”.

7. PoNS TM 4.0 Device & MOA Theory
Targeted Nerves
The trigeminal and facial nerves are stimulated by an electro array placed on the tongue
Stimulation translates into neural impulses, delivered directly into the brain stem, then dispersed throughout the brain
Stimulation seems to affect capacity organization and function of the structures

8. PoNS TM Development and Corporate Timeline
2014 (Q2)
Helius acquired NHC and concurrently closed $7.6M Private Placement
Initiated PoNS 4.0 Development Process
2013 (Q1)
Entered into CRADA with US Army for R&D of PoNS in TBI
2010
PoNS 2.2 Experimental Device Released
2014 (Q4)
Established Scientific Advisory Board led by Dr. Jonathan Sackier
Issued 2 Patents for NINM for Rehabiliation of Brain Function
1990
Tactile Communications and Neurorehabilitation Laboratory (TCNL) Founded at University of Wisconsin-Madison
2015 (Q2)
PoNS 4.0 Released and Manufactured for Registrational Trial
Issued 3rd Patent for NINM for Rehabilitation of Brain Function
Completed recruitment of MS Pilot
’90’s
’00’s
2010–2012
2013
2014
2015
2014 (Q3)
Began TBI Pilot Studies for PoNS at UW-Madison
Completed Commercial Design Specification and received prototype of PoNS 4.0
Began Trading on CSE under HSM Symbol
2007
PoNS 1.0 Experimental Device Developed
2013 (Q1)
NHC founded as a 50/50 joint venture between ANR (inventors of the PoNS) and MPJ HealthCare (medical device commercialization experts).
2015 (Q1)
Modified CRADA to Speed Development of PoNS 4.0
Enrolled first subjects in MS Feasibility Study
Listed on OTCQB under HSDT symbol
Closed of CAD $2.2M Private Placement

9. PoNS TM retrospective analysis by Optum Health
6/3/ Optum conducted a third-party retrospective analysis to test statistical significance of patient outcomes from the use of PoNSTM device plus physical therapy versus physical therapy alone (standard of care)
Compiled data from 4 studies in patients with resistant neurological conditions secondary to disease or trauma
In these studies, patient outcomes were evaluated using the following ‘patient outcome tests’:
Dynamic Gait Index (DGI), Sensory Organization Test (SOT), Multiple Sclerosis Impact Scale-29 (MSIS-29) and Activities-specific Balance Confidence Scale (ABCScore).
Data across studies were aggregated by ‘patient outcome test’ and tested for statistical significance
CONCLUSION:
The use of the PoNSTM device in conjunction with physical therapy produced a statistically significant better outcome in patients with resistant neurological conditions secondary to disease or trauma

10. Data Analysis - Comprehensive
The Dynamic Gait Index (DGI) is a clinical tool to assess gait, balance and fall risk. It evaluates not only usual steady-state walking, but also walking during more challenging tasks. It consists of 8 functional walking tests that are performed by the subject and marked out of three, according to the lowest category which applies. 24 is the highest individual score possible and scores of 19 or less have been related to increase incidence of falls.
The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-report rating scale for measuring the physical and psychological impact of multiple sclerosis (MS).
The sensory organization Test is a composite score is calculated and normalized for age and gender. Changes in Composite score of 5 points or greater are considered clinically significant.

11. A Spectrum of Symptoms Multiple Sclerosis Impact Scale (MSIS-29)
Case Studies – Multiple Sclerosis
A Spectrum of Symptoms Multiple Sclerosis Impact Scale (MSIS-29)
Anxiety
Sleep
Wellbeing
Bladder/Bowel Control
Spasms in Limbs
Tremors
Using Hands
Stiffness
Clumsiness
Balance
Concentration
Limits on Work
Slowness
Self Transport
Clinically Significant
Psycho-Social
Physical
Physical Tasks
Impatience
Depending on Others
Mental Fatigue
Limits on Mobility
Heavy Limbs
Uncoordinated
Confidence
Moving Indoors
Grip
Carry Things
Limits on Socializing
Spontaneity
Worry about MS
Severity of Symptoms
Not at All
Extreme
One measure is a standard SELF-survey capturing 20 physical and 9 psychological measures of the impact of MS on daily living.
Notice impact on symptoms common in multiple neurological disorders:
MS, PD, TBI, Stroke, perhaps even cognitive and psycho-social disorders 11 11

12. Case Studies – Traumatic Brain Injury (TBI)
Pilot Study evaluating Balance using the Sensory Organization Test (SOT) after PoNSTM + Exercise
Sensory Organization Test (SOT) is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. There are 6 independent sensory conditions tested, each condition consisting of three twenty second trials.
▲ of 5.0 = Clinically Significant Change
SOT Points
Four female subjects, mean 48.3 y/o
Moderate, close-head non-penetrating, concussive TBI
9-11 Glasgow Coma Scale

13. Traumatic Brain Injury (TBI)
$76.5B Cost to US /$10B+Total Estimated Market Size
No SUITABLE ALTERNATIVE FOR TREATMENT AVAILABLE
Military
Athletic / Civilian
Common Types of TBI due to Military Activity
Explosive blast injury
Overpressure
Penetrating injury
Diffuse axonal injury
Causes of Civilian TBI
Blunt trauma
Motor Vehicle Accident
Sports Related Injury
Assaults
100,000+ cases of TBI reported in US
30,000/year Active Duty Soldiers TBI
300,000 Retired Soldiers TBI
28% of patients at Walter-Reed result in treatment >$100,000,000 annually
30% Chronic Disability
$5B+ Estimated Market Size (mild to moderate)
PPAE guidance:
This is a stacked Column chart showing Army, DHP & Other funding in $M
Other: is funds POM’d by others
RAD2 Chart version from “RAD2 Program Plan Supporting Spreadsheet_bjw_rwp 25June12”.
ESTIMATED MARKET SIZE
5.3M living with TBI related disability1
1.75M cases of TBI reported in U.S./year 30% result in chronic symptoms
1) 2010 – 2012, United States Source: _______

14. US Army Medical Research and Material Command
Cooperative Research and Development Agreement (CRADA) with the US Armed Forces signed January 2013
US Army commits non-dilutive funding and resources for PoNS™ research
US Army provides regulatory expertise, access to special regulatory relationship with the FDA, facilities and personnel as needed
Recent Agreement Modification signed January 2015
Transfers mTBI trial sponsorship to Helius
Expedites commencement of mTBI trial, now projected for Q2:15
Expands PoNS™ research into tinnitus, PTSD and sleep disturbances

15. Regulatory Pathway
FDA deemed the PoNSTM device a ‘non-significant risk device’
Does not pose a significant risk to human subjects
90-day regulatory review upon submission for de-novo clearance
Seeking a de-novo clearance from the FDA in 2 indications
Balance disorder related to mild to moderate TBI
Reviewed and cleared the registrational trial protocol
Primary endpoint is improvement in balance
Gait and Balance disorders related to MS
Parallel path to EU CE Mark and Health Canada MDL approval

16. PoNS™ Clinical Trials in TBI
Chronic balance deficit due to mild-to-moderate Traumatic Brain Injury (TBI)
Feasibility study underway at the TCNL at the University of Wisconsin-Madison with 44 patients
Pivotal Phase III trial to commence in Q2:15 at
Oregon Health and Science University (Portland, OR)
Orlando Regional Medical Center (Orlanda, FL)
McGill University’s Montreal Neurological Institute and Hospital (Montreal, QC)
120 patient double-blind, active control study
Primary endpoint is improvement in chronic balance deficit at 5-weeks
Interim data results at 90 patients

17. Obtain Clearance/ Approval
PoNS ™ Clinical Milestones
Pre-clinical
Pilot Study
Begin FDA Reg. Trial
Complete FDA Reg. Trial
Submit FDA Filing
Obtain Clearance/ Approval
PoNS™ 4.0 Device | Cranial Nerve Non-Invasive Neuromodulation + Exercise
CLINICAL STAGE PROGRAMS
Traumatic Brain Injury
Q2:15
Q4:15
Q2:16
Q3:16
Multiple Sclerosis
Q2:17
Q3:17
Q4:17
*Results Q4:15
* Interim data from Montreal Neuro pilot 4Q15

18. Quality ManagementSystem
PoNS™ Device Design Milestones
Phase 1
Specification Lock
Design Lock
Mfg. Clinical Supplies
Mfg.
Production
Quality ManagementSystem
PoNS™ 4.0 Device | Design and Manufacturing Timeline
Timeline 
Q2:14
Q3:14
Q4:14
Q2:15
Q3:15
Q4:15

19. Intellectual Property
Issued Patents:
September 2014 – US Patent No. 8,849,407
Skin Stimulation + physical therapy = Therapeutic outcome
December US Patent No. 8,909,345
Oral Cavity Stimulation + Physical exercise = Therapeutic output
March 2015 – US Patent No. 9,020,612
Oral Cavity Stimulation + Cognitive exercise = Therapeutic outcome
Pending Patent Applications:
Skin stimulation + cognitive exercise = Therapeutic output
26 Design and utility pending patent for the PoNS 4.0 commercial device
Future Patent Applications:
Proskauer Rose LLP aiding in expansion of IP development

20. Healthcare Transaction Model
Patient
Self Identified based on DTC Promotion
Healthcare Provider Identified
Patient purchases PoNS device though cash or private insurance reimbursement from the Accredited Physical therapy center/Therapist
Physician
Prescribes PoNS device
Prescribes Certified Physical Therapy Center/Therapist accredited in PoNS training
Prescribes course of 14 weeks of therapy
Accredited Physical Therapy Center
Orders PoNS device from Helius and direct shipped from OEM to the patient at first visit
Performs training for patient based on diagnosis and needs
Obtains reimbursement for services from private and public insurance
Discharges patient to home therapy
Physical Therapy Phone Center
Monitors the patient daily for the first two weeks of at home therapy through phone or video interphase
Monitors the patient weekly (3-14) basis to ensure compliance and adherence to treatment protocol
Directs the patient back to the physician for assessment when 14 weeks of therapy are over
Cycle continues until physician is satisfied patient has sufficiently recovered

21. 1,750 million, 550,000 with Chronic disability
Market Opportunity
# of existing Patients
New Patients/ year
Multiple Sclerosis
1,000,000
10,000
TBI
5,300,000
1,750 million, 550,000 with Chronic disability
Parkinson’s
750,000
60,000
Stroke
7,000,000
795,000
Alzheimer’s Disease
5,400,000
1,200,000
Depression
21,000,000
11,000,000
PTSD
15,400,000
8,225,000
ADHD
5,752,000
2,600,000
Chronic Pain
100,000,000
5,000,000
PoNS device + physical or other therapy potentially treats the symptoms of multiple brain disorders/trauma
Each Indication requires clinical trial (16 months and $3M of funding)

22. PoNS™ Initial Therapeutic Focus Areas
Discovery / Preclinical
Pilot Study
FDA Registration Clinical Trial
PoNS™ 4.0 Device | Cranial Nerve Non-Invasive Neuromodulation + Exercise
CLINICAL STAGE PROGRAMS
Traumatic Brain Injury
Q2:15
Multiple Sclerosis
Q2:16
Preliminary Data / Direct Evidence
PRELIMINARY EVALUATION STAGE PROGRAMS
Stroke
Tinnitus (Ringing of Ears)
Chronic Pain
Post-traumatic Stress Disorder (PTSD)
Sleep Disorders

23. Financial Information
CSNX: HSM | OTCQB: HSDT
Market Cap
$138M
Current Shares Outstanding:
64M Shares
Fully Diluted Shares:
78M Shares (incl. Options and Warrants)
Cash:
$1.5M
Debt: -
Financings
$1.8M from private placement closed April 30, 2015

24. Summary
Proprietary breakthrough non-invasive technology to relieve neurological symptoms through precise neuro-stimulation via the tongue
Immediate addressable market of over $5B upon FDA clearance; market penetration potential in additional neurological indications
High unmet need, limited existing treatment alternatives
DOD partnership helps defray development cost and is our first significant customer
Anticipated commercialization roll-out 2H 2016

25. US Investor Contact
Todd James, Senior Vice President, The Trout Group LLC
Helius Medical Technologies, Inc. 
41 University Drive, Suite 400 Newtown, PA 18940 T: E: W:

26. Appendix

27. Capital Structure & Financial Information
Shares
Shares outstanding
63,968,461
Stock Options
4,920,000
Warrants from financings
8,882,032
Fully Diluted
77,770,493
Ownership*
# Shares
Management
33,000,000**
* all approximations above
Stock Options
CAD $0.60 Exercise Price
3,770,000
CAD $2.52 Exercise Price
100,000
CAD $2.92 Exercise Price
550,000
CAD $2.96 Exercise Price
400,000
CAD $3.20 Exercise Price
Total
4,920,000
** Included in Fully Diluted Share Count
Financial Overview:
$7.2M investment ($3M from NIH, $4.1 private non-dilutive donations)
$6.9M from concurrent financing with new listing
$1.8M from private placement closed April 30, 2015
$1.5M Total in treasury
Non-Dilutive Commitment: US Army
$11M est. for development of registration trial and regulatory submission
$20.0M est. for development of further indications (Tinnitus, PTSD and Sleep Disturbance)
$9.0M non-dilutive investment by US Army to date
Warrants
CAD $1.00 Exercise Price
8,430,000
CAD $3.00 Exercise Price
452,032
Total
8,882,032

28. Scientific Advisory Board (SAB) Established
Jonathan Sackier, M.D., Chairman Scientific Advisory Board
Ron Alterman, M.D., M.B.A.
Harvard professor
Neurosurgeon at Beth Israel (BIDMC)
Expertise in movement rehabilitation
D. James Surmeier, M.D.
Chair of the Department of Physiology and Director of Parkinson’s Disease Research Center at Northwestern University
Carl Hauser, M.D.
Director of Trauma at BIDMC
visiting professor of Surgery at Harvard Medical School
Reggie Edgerton, M.D., Ph.D
Professor in the Departments of Neurobiology, Integrative Biology and Physiology and Neurosurgery at UCLA
Member of the Brain Research Institute
Scott Parazynski, M.D.
Former NASA astronaut
Inventor/leader in the medical device/research fields
Rick Celebrini, Ph.D
Physiotherapist, Founder of Fortius Institute,
Retired Canadian professional soccer player
Canadian Medical team member at 3 Olympic games
Head of Sports Medicine and Science for the Vancouver Whitecaps FC
Catherine Cho, M.D. MSCR
Assistant Professor in the Department of Neurology at
The Icahn School of Medicine at Mount Sinai
Gale Pollock, R.N.,
Former Commander of the US Army Medical Command
Acting Surgeon General of the Army
Fellow at the American College of Healthcare Executives, American Academy of Nursing and National Board of Corporate Directors.
Jennifer Sweet,  M.D.
Department of Neurological Surgery University Hospitals Case Medical Center

29. Competitive Landscape
Helius
NeuroSigma
Cyberonics and Others
Cefaly
Annual Sales
None
$243M
Just approved FDA
Type of Device
Non Invasive
Non Invasive and Minimally Invasive
Invasive: Implantable
Forehead Cutaneous stim.
Approved Indications
Drug Resistant Epilepsy
Migraine Headache
Units Sold
65,000 --
Anticipated Indications
TBI, MS, Parkinson and Stroke
Drug resistant Epilepsy, Post Traumatic Stress Disorder, Obesity, Cachexia
Targeted Nerve
Trigeminal and Facial
Trigeminal
Vagus
Product Name
PoNS
Monarch
VNS
Product Classification
TBD
Class III
Class II
FDA Cleared No
Yes

30. Financial Results & Projections
Cyberonics Case Study
Focus on neuromodulation: developed and markets VNS Therapy System, a vagus nerve stimulation device implantation for refractory epilepsy and treatment resistant depression
Ticker:
CYBX
Mkt Cap:
$1.3bn
VNS Device:
Vagus Nerve Stimulation
MOA:
Unknown
Indication: Epilepsy, Depression
FDA-Approved
Marketed WW
Unmet medical need for treatment refractory epilepsy patients, estimated 9mm people with epilepsy
>400,000 U.S. patients indicated for VNS Therapy
Key Indication
VNS Therapy System
Surgically implanted medical device delivering electrical pulsed signals to vagus nerve
MOA not fully understood, but positive clinical results
Clear evidence towards seizure reduction in refractory epilepsy
Financial Results & Projections
Over $250M in annual Revenues
Estimated >10% y/y growth
Market Conditions
Majority of IP expired in 2011, but no new competition entering in VNS epilepsy space
Continued demand for patient therapies in neuromodulation
>3,000 physicians using VNS Therapy
>100,000 implants to date
Cyberonics provides important precedent for Helius adoption and success

31. Operational Milestones
PoNSTM (4.0) with OEM contract medical device manufacture and design company Ximedica
Design work complete with first clinical scale capacity Q1:15
Generate Army Deployment Plan Q3:16
Ensure VA system PT infrastructure is created for maximum deployment efficiency
Create Physical Therapy Support Network
Develop partnership with national suppliers by June 2015
Develop certification plan for PTCs by May 2015
Develop home base compliance monitoring structure ready to deploy Q2: 16
Obtain CPT reimbursement code for device reimbursement Q1:17
Develop International Regulatory Submission Package Q1:15
Drive submission to Health Canada on a parallel track to the US submission